Search clinical trials for: PF-06804103 + Palbociclib +Letrozole

Total 93 results

Pfizer

Completed

PF-06804103 Dose Escalation in HER2 Positive and Negative (Negative Only in Part 2) Solid Tumors

Breast Neoplasms

Spain, Korea, Republic of, United States, Australia, Italy, Russian Federation
Pfizer

Terminated

First in Patient Study for PF-06840003 in Malignant Gliomas

Astrocytoma | Malignant Glioma | Oligodendroglioma

United States
Pfizer

Recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer

China, United States, Japan, Mexico
MedSIR
Pfizer

Completed

Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 - (DxCARTES)

Breast Cancer

Spain, Portugal
Pfizer

Active, not recruiting

Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy

Metastatic Breast Cancer

United States
Pfizer

Completed

Study to Evaluate Overall Survival in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Letrozole

Breast Cancer

Japan
Pfizer

Recruiting

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

Breast Cancer | Solid Tumors

China, United States, Mexico, Bulgaria, Spain, Brazil, Czechia, Argentina, South Africa
Shengjing Hospital

Recruiting

Palbociclib Combined With an Aromatase Inhibitor in Breast Cancer

Breast Cancer

China
Latin American Cooperative Oncology Group
Pfizer

Completed

Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer (LACOG1018)

Ovarian Cancer

Brazil
Pfizer

Terminated

Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer

Early Breast Cancer (Phase 2) | Advanced Breast Cancer (Phase 1b)

Spain, Sweden, Italy, Belgium
Pfizer

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors (KAT6)

Locally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung Cancer

United States, China, Australia, Korea, Republic of, Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial

Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
Weill Medical College of Cornell University

Recruiting

Combined Immunotherapies in Metastatic ER+ Breast Cancer

Breast Cancer

United States
University of Colorado, Denver
Pfizer; Criterium, Inc.; Cascadian Therapeutics Inc.

Completed

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Breast Cancer

United States
International Cancer Research Group, United Arab...
King Saud University Medical City, Riyadh, Saudi Arabia; Max-Planck-Institut... and other collaborators

Recruiting

Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. (ICRG0201)

Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

Algeria, Jordan, Saudi Arabia
University of Kansas Medical Center
Pfizer

Terminated

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

HER2-positive Breast Cancer | Breast Cancer Metastatic

United States
Weill Medical College of Cornell University

Withdrawn

CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer (CIMER)

Breast Cancer
Georgetown University
University of Chicago; Thomas Jefferson University

Completed

Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer (PALINA)

Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
SOLTI Breast Cancer Research Group
Novartis; Alliance Foundation Trials, LLC.

Recruiting

Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype (HARMONIA)

Metastatic Breast Cancer

United States, Spain, Portugal
Pfizer
Arvinas Estrogen Receptor, Inc.

Recruiting

A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3)

Breast Cancer

United States, China, Spain, Hungary, Japan, Australia, Brazil, Italy, Slovakia, Switzerland
Nordic Society of Gynaecological Oncology - Clinical...
European Network of Gynaecological Oncological Trial Groups (ENGOT); Grupo... and other collaborators

Completed

Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer

Endometrial Cancer

Denmark
NSABP Foundation Inc
Royal Marsden NHS Foundation Trust; Pfizer; Institute of Cancer Research, United...

Completed

A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer (PALLET)

Breast Cancer | Breast Tumors | Breast Carcinoma

United Kingdom, United States, Canada
UNICANCER
Pfizer

Active, not recruiting

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection (PADA-1)

Metastatic Breast Cancer

France
Avenzo Therapeutics, Inc.

Recruiting

Study of ARTS-021 in Patients With Advanced Solid Tumors

Solid Tumors

United States
Pfizer

Completed

A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

Neoplasms | Breast Neoplasms

Japan
Organisation for Oncology and Translational Research

Unknown

Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women

ER Positive, HER2 Negative Breast Cancer

China
Pfizer

Terminated

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Australia, Japan
Pfizer

Completed

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Breast Cancer

Korea, Republic of, United States, Spain, Germany, Ireland, Hungary, Canada, France, Italy, Russian Federation, South Africa, Ukraine
Alliance Foundation Trials, LLC.
Pfizer; Syneos Health; UNICANCER; German Breast Group; SOLTI Breast Cancer Research... and other collaborators

Active, not recruiting

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA)

HER-2 Positive Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States, Spain, France, Italy, Germany, Australia, Portugal, New Zealand
Dana-Farber Cancer Institute
Pfizer

Recruiting

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Pancreatic Cancer | Solid Tumors | Lung Cancer Squamous Cell | Head & Neck Cancer

United States
Dana-Farber Cancer Institute

Completed

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Solid Tumors | KRAS Mutant Non-Small Cell Lung Cancer

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

Recurrent Childhood Medulloblastoma | Childhood Choroid Plexus Tumor | Childhood Ependymoblastoma | Childhood Grade III Meningioma | Childhood High-grade Cerebellar Astrocytoma | Childhood High-grade Cerebral Astrocytoma | Childhood Medulloepithelioma | Recurrent Childhood Anaplastic Astrocytoma | Recurrent... and other conditions

United States
MedSIR
Pfizer

Completed

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA)

Breast Cancer | Advanced Breast Cancer | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Spain, Germany, France, United Kingdom, Italy, Slovenia
Borstkanker Onderzoek Groep

Active, not recruiting

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Breast Neoplasm Female

Netherlands
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

United States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
Istituti Clinici Scientifici Maugeri SpA

Completed

Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy

Female | Neoplasm Malignant | Breast

Italy
Thomas Hatschek

Active, not recruiting

Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases (PREDIX LumB)

Early-Stage Breast Carcinoma | Estrogen Receptor Positive Tumor

Sweden
Pfizer

Completed

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Breast Cancer

United States
Sanofi

Terminated

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer (AMEERA-5)

Breast Cancer

United States, Russian Federation, Italy, Australia, Belgium, France, Japan, Ukraine, Netherlands, Argentina, Canada, Portugal, Spain, Austria, Brazil, Bulgaria, Chile, China, Czechia, Finland, Georgia, Germany, Hungary, Korea, Republic... and more
Pfizer

Active, not recruiting

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Advanced Breast Cancer

China
Pfizer

No longer available

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Advanced Breast Cancer (Female)

Canada, United States
Pfizer

Completed

Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer

Breast Cancer

Australia, India
Shengjing Hospital

Not yet recruiting

Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy

Breast Cancer

China
Pfizer

Active, not recruiting

A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]

Breast Neoplasms

China, Taiwan, Hong Kong, Singapore, Thailand
Peter MacCallum Cancer Centre, Australia

Recruiting

Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer (PALVEN)

Breast Neoplasm Female

Australia
Pfizer

Completed

Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate

Advanced Breast Cancer Female

Mexico, Argentina, Brazil, Colombia
AstraZeneca

Recruiting

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

ER-Positive HER2-Negative Breast Cancer

United States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
National Taiwan University Hospital

Recruiting

A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC (ORACLE-RIPA)

Breast Cancer | Hormone Receptor-positive Breast Cancer | Hormone Therapy

Taiwan
Pfizer

Completed

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

Breast Neoplasms

United States, Canada, Spain, United Kingdom, Australia, Belgium, Korea, Republic of, Japan, Czechia, France, Germany, Hungary, Ireland, Italy, Poland, Russian Federation, Taiwan, Ukraine
Dana-Farber Cancer Institute
Pfizer

Completed

Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer

Breast Cancer

United States

Search clinical trials for: PF-06804103 + Palbociclib +Letrozole

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Finland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations